Rockwell Medical price target lowered to $9 from $11 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Rockwell Medical to $9 from $11 and keeps a Buy rating on the shares following the Q4 report. The analyst remains “broadly optimistic” regarding Rockwell Medical’s prospects and its positioning in a hemodialysis concentrates market “that essentially constitutes a duopoly,” but says the company’s forward guidance from a sales perspective was less bullish than hoped.